NOVARTIS AG's new triple-antibody drug has been approved for clinical use in China, targeting systemic lupus erythematosus
I'm PortAI, I can summarize articles.
Novartis's Class 1 new drug PIT565 has obtained a new clinical trial implicit approval in China, aimed at treating systemic lupus erythematosus (SLE). The drug is a tri-specific antibody targeting CD3/CD19/CD2 and is currently in the international multi-center Phase 1 research stage. This approval marks the entry of PIT565 into the clinical development phase in China, potentially overcoming T cell exhaustion through co-stimulation of CD2, enhancing the depth and duration of patient responses
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments